http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114026424-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c87b1f7158bec499783fa1b27aad08c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57423 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2020-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0d956aaca69a6ba2932e4f2f55ebe43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1683f0a4cb16e03389be0c194e11d4ec http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d211987d24a34e4d4d99e25aa69423fc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7de9c5e0fc7e537618b782e4306fa9b7 |
| publicationDate | 2022-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114026424-A |
| titleOfInvention | Method for determining the likelihood of lung cancer |
| abstract | The present invention relates to methods of determining the likelihood of the presence of lung cancer in a subject. The method comprises determining from a population of vesicles isolated from a biological sample of the subject selected from the group consisting of catalase (CAT), C-X-C motif chemokine receptor 4 (CXCR4), superoxide Levels of biomarkers of dismutase 3 (SOD3) and surfactant protein B (SFTPB), wherein changes in biomarker levels compared to a reference are indicative of the likelihood of the presence of lung cancer in the subject. In a preferred embodiment, the presence of non-small cell lung cancer (NSCLC) is determined based on an increase in the level of the marker based on plasma-derived exosomes compared to healthy subjects. The present disclosure also relates to determining lung cancer progression or responsiveness of a subject with lung cancer to anticancer therapy based on the biomarkers. |
| priorityDate | 2019-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 257.